1
|
Larson‐Nath C, Bashir A, Herdes RE, Kiernan B, Lai J, Martin N, Misner N, Pandey A, Puri K, Zong W, Duro D. Term infant formula macronutrient composition: An update for clinicians. J Pediatr Gastroenterol Nutr 2025; 80:751-759. [PMID: 39930711 PMCID: PMC12066912 DOI: 10.1002/jpn3.70002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2024] [Revised: 12/07/2024] [Accepted: 12/14/2024] [Indexed: 05/13/2025]
Abstract
Protein, carbohydrates, and fats comprise the macronutrient components of infant formulas. While all infant formulas in the United States meet specific nutrition standards, the macronutrient composition of formulas is diverse. Each macronutrient in the formula may play a role in treating or managing the disease. In addition, many formulas are marketed as resembling the composition of human milk or improving symptoms such as colic and irritability. For these and other reasons, families are often interested in different formula properties. When choosing a formula for their infant families, they may reach out to clinicians for advice. Therefore, clinicians need to understand the macronutrient composition of the formulas their patients are using. This manuscript discusses the macronutrient composition of term infant formulas and indications of the use of different macronutrient components.
Collapse
Affiliation(s)
- Catherine Larson‐Nath
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of PediatricsUniversity of MinnesotaMinneapolisMinnesotaUSA
| | - Anam Bashir
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of PediatricsChildren's Hospital of PhiladelphiaPhiladelphiaPennsylvaniaUSA
| | - Rachel E. Herdes
- Division of Pediatric Gastroenterology, Hepatology and NutritionStanford University School of MedicineStanfordCaliforniaUSA
| | - Bridget Kiernan
- Division of Pediatric Gastroenterology, Hepatology and NutritionNYU Langone HealthNew YorkNew YorkUSA
| | - Joanne Lai
- Division of Pediatric Gastroenterology, Hepatology and NutritionIcahn School of Medicine at Mount SinaiNew YorkNew YorkUSA
| | - Nicole Martin
- Clinical Nutrition, Children's WisconsinMilwaukeeWisconsinUSA
| | - Nicole Misner
- Division of Pediatric Gastroenterology, Hepatology and NutritionUniversity of South FloridaTampaFloridaUSA
| | - Akash Pandey
- Division of Pediatric Gastroenterology, Hepatology and NutritionUniversity of Central FloridaOrlandoFloridaUSA
| | - Kanika Puri
- Division of Pediatric Gastroenterology, Hepatology and NutritionRiley Hospital for Children at Indiana University HealthIndianapolisIndianaUSA
| | - Wenjing Zong
- Division of Pediatric Gastroenterology, Hepatology and NutritionUT SouthwesternDallasTexasUSA
| | - Debora Duro
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of PediatricsSalah Foundation Children Hospital, Broward HealthFort LauderdaleFloridaUSA
| |
Collapse
|
2
|
McLaughlin F, Fisher J, Atherton M, Coyle C. Evaluating the reflux suppression properties of Gaviscon Infant powder with different milk formulations using an in vitro model of the infant stomach. Sci Rep 2025; 15:4787. [PMID: 39922843 PMCID: PMC11807092 DOI: 10.1038/s41598-025-88638-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2024] [Accepted: 01/29/2025] [Indexed: 02/10/2025] Open
Abstract
Gastroesophageal reflux (GER) is common in babies and infants and is characterized by effortless regurgitation (with or without vomiting), which is a common symptom of other infant conditions, including cow's milk protein allergy (CMPA). Various milk formulations are commercially available to help manage GER and CMPA symptoms (extensively hydrolyzed [eHF], partially hydrolyzed [pHF], and amino-acid formulas [AAF]). We aimed to understand if an alginate product (Gaviscon Infant powder) worked as intended in the presence of different milk formulations. A previously evaluated artificial infant stomach model simulated an internal pressure-inducing reflux event (five reflux events performed at 5 min intervals). Suppression activity of Gaviscon Infant combined with eHF, pHF, and AAF was assessed by measuring the height that the refluxate event traveled up a tube mimicking the infant esophagus, alongside a benchmark unhydrolyzed formulation (uHF) with Gaviscon Infant and a negative control without Gaviscon Infant. Each experiment was repeated six times per formulation in a random order. Gaviscon Infant combined with each milk formulation produced a lower height of refluxate versus the negative control. When formulations combined with Gaviscon Infant were grouped by category (eHF, pHF, AAF), two or more products from each category showed a lower refluxate height than the benchmark (uHF). There was a significant difference in median refluxate height (p = 0.0011 in Wilcoxon rank sum test) when comparing Gaviscon Infant combined with eHF against Gaviscon Infant combined with pHF, AAF, or uHF (benchmark). Refluxate height did not change significantly between events one and five for each milk formulation combined with Gaviscon Infant. In an artificial infant stomach model, Gaviscon Infant combined with different milk formulations (uHF, eHF, pHF, AAF) produced a lower refluxate height compared with a negative control (uHF without Gaviscon Infant), suggesting that Gaviscon Infant suppresses reflux as intended when used with different milk formulations.
Collapse
Affiliation(s)
- Fiona McLaughlin
- Reckitt Healthcare Ltd, Digestive Relief, Dansom Lane, Hull, HU8 7DS, UK.
| | - Jeanine Fisher
- Technostics Limited, Research & Development, Daisy Building, Castle Hill Hospital, Cottingham, HU16 5JQ, East Yorkshire, UK
| | - Mark Atherton
- Technostics Limited, Research & Development, Daisy Building, Castle Hill Hospital, Cottingham, HU16 5JQ, East Yorkshire, UK
| | - Cathal Coyle
- Reckitt Healthcare Ltd, Digestive Relief, Dansom Lane, Hull, HU8 7DS, UK
| |
Collapse
|
3
|
Koeder C. Toward Supplementation Guidelines for Vegan Complementary Feeding. Food Sci Nutr 2024; 12:10962-10971. [PMID: 39723035 PMCID: PMC11666816 DOI: 10.1002/fsn3.4565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2024] [Revised: 10/04/2024] [Accepted: 10/10/2024] [Indexed: 12/28/2024] Open
Abstract
Previously published recommendations for vegetarian (including vegan) diets for children have highlighted the need for vitamin B12 supplementation. Increased attention to several other key nutrients (including iodine, vitamin D, calcium, and iron) has also been recommended. However, an overview focusing on supplementation guidelines, specifically for vegan infants, has not been published, and a potential requirement for iodine and/or selenium supplementation in (some) vegan infants has not been discussed. Vegan complementary feeding should be supplemented (particularly with 5 μg/day of vitamin B12 and 10 μg/day of vitamin D). Iodine should be supplemented (up to 110 μg/day) if the intake of breast milk and infant formula is low, and selenium supplementation (5 μg/day) should be considered in regions with low soil selenium levels. Caution is required to avoid excessive intakes of iodine and particularly selenium. Supplements for vegan infants are on the market, and observational studies are urgently needed to assess the nutrient intake (including supplements) and status in vegan infants.
Collapse
Affiliation(s)
- Christian Koeder
- Faculty of Medicine, Institute for Prevention and Cancer EpidemiologyUniversity of FreiburgFreiburgGermany
| |
Collapse
|
4
|
Alfonso RMJ, Rubí IAK, Manuel TME, Roberto CB, Alejandra RCM, de Jesús MVI, Gabriela AGA, Vladimir BND, Lucía CG, Antonio CBJ, Sergio DM, Esther FFL, Manuel Enrique GPM, Ileana GCJ, Elena HHR, Elena LRA, Héctor MA, Carlos MN, José Antonio OM, Iván OGC, Rubén PV, Nicolás RMJ, Del Mar SDOGM, Gerardo SM, Eugenia URM, Liliana WD, Hideo WKG, Yvan V. Mexican consensus on cow's milk protein allergy. Allergol Immunopathol (Madr) 2024; 52:24-37. [PMID: 38186191 DOI: 10.15586/aei.v52i1.958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 10/04/2023] [Indexed: 01/09/2024]
Abstract
BACKGROUND The aim of this study is to present the current views of a diverse group of experts on the diagnosis and treatment of Cow's Milk Protein Allergy (CMPA) in children under 2 years of age in Mexico. MATERIAL AND METHODS The study, led by a scientific committee of five experts in CMPA, was divided into six phases, including a modified Delphi process. A total of 20 panelists, all of whom were pediatric specialists, participated in administering a comprehensive 38-item questionnaire. The questionnaire was divided into two blocks: Diagnosis and Treatment (20 items each). RESULTS Consensus was reached on all the proposed items, with an agreement rate of over 70% for each of them. As a result, a diagnostic and treatment algorithm was developed that emphasized the reduction of unnecessary diagnostic studies and encouraged breastfeeding whenever possible. In cases where breast milk is not available, appropriate use of hypoallergenic formulas was recommended. In addition, recommendations on treatment duration and gradual reintroduction of cow's milk protein were provided. CONCLUSIONS The recommendations endorsed by 20 Mexican pediatricians through this study are applicable to everyday clinical practice, thereby enhancing the diagnosis and treatment of children under 2 years of age with CMPA. This, in turn, will foster improved health outcomes and optimize the utilization of healthcare resources.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Casas Guzik Lucía
- Pediatric Gastroenterology, Hospital Infantil de Morelia Eva Sámano de López Mateos, Morelia, México
| | | | | | | | | | | | | | | | | | - Méndez Nieto Carlos
- Pediatric Gastroenterology, Hospital Infantil de Especialidades, Ciudad Juárez, Mexico
| | | | | | - Peña Vélez Rubén
- Pediatric Gastroenterology, Hospital General de Puebla Dr. Eduardo Vázquez N., Puebla, Mexico
| | | | | | | | | | | | | | - Vandenplas Yvan
- Pediatric Gastroenterology, KidZ Health Castle, UZ Brussel; Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|
5
|
Jirillo F. Healthy Effects of Milk and Dairy Product Consumption in the Mediterranean Area and Japan. Endocr Metab Immune Disord Drug Targets 2024; 24:1813-1822. [PMID: 38994611 DOI: 10.2174/0118715303289711240703080701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 06/12/2024] [Accepted: 06/12/2024] [Indexed: 07/13/2024]
Abstract
Milk is a food enriched in essential components for human health. Especially, in the Mediterranean area, besides cow's milk, milk from goats, sheep, and donkeys, is largely used. The consumption of animal milk is an important component of the Mediterranean (MED) diet, even if in moderate amounts. Milk is a complete food since it contains proteins, carbohydrates, and fats, as well as micronutrients (minerals and vitamins). Milk-fermented products are largely consumed in the MED diet, such as cheese and yogurt, which are rich in essential metabolites, bioactive compounds, vitamins, minerals, and exopolysaccharides. A large body of evidence suggests that consumption of milk and dairy products does not increase the risk of all-cause mortality, type 2 diabetes, and cardiovascular disease, even if some earlier studies have reported harmful effects associated with their higher consumption. Also, in Japan, despite the lower consumption of milk than in Western countries, intake of bovine milk is associated with healthy effects. The present review describes the effects of the various constituents of animal milk on human health, with special reference to the Mediterranean area and Japan. Experimental data and clinical trials support the ability of milk and dairy products to lower the risk of chronic diseases.
Collapse
|
6
|
Klepper CM, Moore J, Gabel ME, Fleet SE, Kassel R. Pediatric formulas: Categories, composition, and considerations. Nutr Clin Pract 2023; 38:302-317. [PMID: 36815542 DOI: 10.1002/ncp.10954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 12/29/2022] [Accepted: 12/31/2022] [Indexed: 02/24/2023] Open
Abstract
Formulas, liquid nutrition, may be consumed orally or via a feeding tube to provide partial or complete nutrition that a given individual could not obtain using natural food stuffs in their native form. A wide range of commercially available formulas exist, which may be used as sole-source nutrition or in conjunction with other foods. Physicians and dietitians must understand the nature of and indications for specific formulas to treat diseases, provide complete nutrition to patients, and avoid harm. Products vary in macronutrient and micronutrient content and calorie concentration among many other factors. They are formulated specifically for patients of specific ages, correlating to nutritional needs and medical diagnoses. Additionally, formula availability, insurance coverage, mode of consumption, physiologic tolerance, and caregiver preference influence formula selection. Caregivers may also make their own pediatric formulas. We review commercial and homemade pediatric formulas.
Collapse
Affiliation(s)
- Corie M Klepper
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.,Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Joseph Moore
- Department of Clinical Nutrition and Lactation, Children's of Alabama, Birmingham, Alabama, USA
| | - Megan E Gabel
- Department of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA.,Division of Pediatric Gastroenterology, Hepatology and Nutrition, University of Rochester Medical Center, Rochester, New York, USA
| | - Sarah E Fleet
- Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.,Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA
| | - Rachel Kassel
- Department of Pediatrics, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.,Division of Gastroenterology, Hepatology and Nutrition, Birmingham, Alabama, USA
| |
Collapse
|
7
|
Lajnaf R, Feki S, Ben Ameur S, Attia H, Kammoun T, Ayadi MA, Masmoudi H. Cows' milk alternatives for children with cows' milk protein allergy - Review of health benefits and risks of allergic reaction. Int Dairy J 2023. [DOI: 10.1016/j.idairyj.2023.105624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
|
8
|
Clinical Effect of Standardized Dietary Avoidance Therapy on Children with Milk Protein Allergy and Its Effect on Intestinal Flora. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2022; 2022:3362374. [PMID: 35978994 PMCID: PMC9377903 DOI: 10.1155/2022/3362374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 06/27/2022] [Accepted: 06/29/2022] [Indexed: 11/23/2022]
Abstract
Objective The aim of this study is to analyze the clinical effect of standardized dietary avoidance therapy on children with cow milk protein allergy (CMPA) and its effect on the intestinal flora. Methods The clinical data of 200 children with CMPA from our hospital from February 2020 to May 2021 were collected, and they were divided into a study group (n = 100) and a routine group (n = 100) based on different intervention modalities. The routine group received routine treatment, whereas the standardized dietary avoidance therapy was used in the study group. The clinical effects and related intestinal microflora indexes of the two groups were analyzed and compared. Results There was no significant difference in the incidence of related symptoms between the two groups before intervention (P > 0.05), and the conditions of the two groups were improved after intervention. The incidences of skin (2%), digestive tract (3.00%), and respiratory tract (1.00%) in the study group were significantly lower than those in the routine group (14.00%, 18.00%, and 11.00%) (P > 0.05). The time taken for complete remission of symptoms and milk tolerance months in the study group (41.23 ± 23.68, 13.28 ± 6.17) were significantly shorter than those in the routine group (145.14 ± 66.74, 16.17 ± 8.05) (P > 0.05). The values of height, weight, and head circumference (HC) of children in the study group (79.88 ± 2.18, 11.09 ± 1.34, 47.88 ± 0.63) were higher than those in the routine group (76.21 ± 2.34, 9.81 ± 1.18, 45.98 ± 0.59) (P > 0.05). The levels of Lactobacillus and Enterococcus (9.95 ± 0.89, 11.31 ± 1.05) in the study group were higher than those in the routine group (9.11 ± 0.74, 10.38 ± 0.94), and the levels of yeast-like fungi in the study group (3.08 ± 0.24) were lower than those of the routine group (3.82 ± 0.31) (P > 0.05). Conclusion The standardized dietary avoidance therapy is remarkable in the treatment of CMPA, in which the children were able to tolerate ordinary milk earlier, and the intestinal flora was significantly improved, thereby promoting the growth and development of children. It therefore merits clinical promotion.
Collapse
|
9
|
Lexchin JR. Formula choices in infants with cow's milk allergy. CANADIAN FAMILY PHYSICIAN MEDECIN DE FAMILLE CANADIEN 2021; 67:318-319. [PMID: 33980618 PMCID: PMC8115971 DOI: 10.46747/cfp.6705318_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
|